Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

ROSEN, LEADING INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile October 4, 2024

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire October 3, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile October 3, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire October 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

PR Newswire October 3, 2024

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

GlobeNewswire October 3, 2024

ALLR Shareholders With Large Losses Should Contact Robbins LLP for Information About the Allarity Therapeutics, Inc. Securities Class Action

ACCESS Newswire October 2, 2024

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

ACCESS Newswire October 2, 2024

ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire October 2, 2024

ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

ACCESS Newswire October 2, 2024

The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire October 1, 2024

ROSEN, A TOP RANKED LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile October 1, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming Deadlines - ALLR

ACCESS Newswire October 1, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics

Newsfile October 1, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Allarity Therapeutics, Inc. to Contact the Firm Today!

ACCESS Newswire October 1, 2024

Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm

ACCESS Newswire September 30, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Allarity Therapeutics, Inc. to Contact the Firm Today!

ACCESS Newswire September 30, 2024

The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.

ACCESS Newswire September 29, 2024

ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Business Wire September 29, 2024

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALLR

Newsfile September 29, 2024